Genomic sequencing leader Illumina has agreed to acquire proteomics firm SomaLogic from Standard BioTools for up to $425 million. The acquisition enhances Illumina’s multiomics portfolio by integrating SomaLogic’s DNA aptamer-based protein detection technology with Illumina’s NGS platforms. The deal includes cash upfront, milestone payments, and royalties. The combined capabilities aim to accelerate biomarker discovery and disease profiling. This strategic move underscores Illumina’s commitment to expanding its footprint beyond genomics into advanced protein analysis platforms, anticipating growth in precision medicine applications.